Demonstration at AIPAC of one of Yissum's AMAZING technologies that allows blind people to HEAR colors.
Professor emeritus Marta Weinstock-Rosin at the Hebrew University of Jerusalem’s pharmacology department has spent years studying drug treatments for degenerative diseases of the central nervous system.
Her research there ranged from how salt raises blood pressure to developing drugs for Alzheimer’s, including rivastigmine (Exelon).
Yissum presents the pipeline of the future: This is where the Start Up Nation begins.
The promising technology is based on years of research at the Hebrew Univresity's Faculty of Agriculture, and was licensed to the company by Yissum.
Novel sodium-ion battery is an environmentally friendly, economic and efficient solution for a variety of applications including electric vehicles and stationary storage for renewable energies
Study was published in the prestigious Nature Communications Journal
The Jerusalem-based start-up said that half of the patients have already been enrolled in the Phase II clinical trial that will include 80 patients with newly diagnosed metastatic pancreatic cancer and have have yet to start chemotherapy. The trial includes two treatment groups of 40 subjects each. The control group is allocated to standard chemotherapy for pancreatic cancer, and the treatment group will receive TL-118 in addition to standard-of-care chemotherapy.
A home-based learning program frm the Hebrew University of Jerusalem is helping families in Indigenous and disadvantaged communities better prepare their children for their first years of education.
Researchers at the Hebrew university of Jerusalem have created a molecule that could potentially lower diabetic patients' higher risk of developing dementia or Alzheimer's disease.
Israel’s beloved singer Arik Einstein died on November 26, at age 74, from a ruptured aortic aneurysm. This condition is an abnormal ballooning of the body’s main artery that can lead to fatal internal bleeding.
Abdominal aortic aneurysm (AAA) is the 13th leading cause of death in most Western countries, and more than 200,000 new cases are diagnosed annually in the US alone.
If aneurysms could be treated early to prevent worsening, the incidence of rupture and death would fall dramatically. And that is the aim of a patented technology from the Hebrew University.
Prof. Raz Yirmiya, director of the Hebrew University’s Psychoneuroimmunology Laboratory, and his doctoral student Tirzah Kreisel, together with colleagues in Yirmiya’s lab and at the University of Colorado, showed that changes in one type of non-neuronal brain cells – microglia – play a role in the development of depression following chronic exposure to stress.
Encouraged by the findings, the Hebrew University’s technology transfer company, Yissum, has applied for a patent for the treatment of some forms of depression by several specific microglia-stimulating drugs.
HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy.
Yissum presents new oxidation-resistant copper nano-inks with a low sintering temperature (lower than 150oC), which enables the printing of low-cost conductive patterns on heat sensitive plastic substrates. Due to these traits, the new inks, developed by Prof. Shlomo Magdassi, from the Institute of Chemistry and the Center for Nanoscience and Nanotechnology can be tailored for a variety of applications, including ink-jet, flexography and screen printing.
Researchers at the Hebrew University of Jerusalem have for the first time worked out how even non-antibiotic resistant bacteria survive antibiotic treatment. The study, which was published this week in the journal Nature Communications, could pave the way for improved therapies for treating bacterial infection.
New results of a 20-year research conducted by Prof. Itamar Gati at the Hebrew University bring bad news and good for gender gaps in the labor market.
A successful joint collaboration between researchers at the Hebrew university of Jerusalem and the startup company TyrNovo may lead to a potential treatment of brain diseases. The researchers found that TyrNovo's novel and unique compound, named NT219, selectively inhibits the process of aging in order to protect the brain from neurodegenerative diseases, without affecting lifespan.
If the phrase “A better life through science” hasn’t yet been copyrighted, Yissum, the technology transfer company of Hebrew University, may want to grab it. From medicine to environmental technology to information systems, Hebrew U scientists have developed a wide range of important technologies, and thanks to Yissum, those technologies are now available to help people around the world.
Germany's Merck KGaA (XETRA: MRK) has increased its stake in Qlight Nanotech Ltd. to 50%, after a further investment of several million dollars in the Yissum Technology Transfer Company of the Hebrew University of Jerusalem portfolio company. Qlight will use the investment to expand development of its semiconductor nanoparticle-based technology and to address a broader customer base.
The agreement sets the stage for a collaborative research consortium in fields of mutual interest, including pediatric translational research.
Melodea Ltd. announced today that it has been awarded above 1,000,000 Euro in 3 projects of the European Union Seventh Framework Program (FP7).
Yissum Research Development Company, the tech transfer arm of Hebrew University of Jerusalem, is seeking business partners to help commercialize an eco-friendly water purifier for aquariums.